The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.
Strong phase II data from Novo Nordisk’s pipeline-hope semaglutide gives cause for optimism for chief science officer Mads Krogsgaard Thomsen, who believes Novo holds a new generation of obesity medicine.
Since Viagra lost patent on June 24, 2013, generic versions of the drug have made the price drop by a staggering 97 %, according to a new analysis from a Danish pharmacy association. It could save Danish consumers millions per year.
Novo Nordisk leads the way when it comes to medical treatment of obesity. According to Sydbank analyst Søren Løntoft Hansen, the brand new results from a phase II clinical trial with pipeline jewel semaglutide more than meet FDA’s requirements for obesity drugs.
Scandion Oncology, a spinoff from Saniona, has high hopes for the company’s candidate drug for the treatment of cancer. The drug has already been through clinical phase I and the plan is to begin phase II clinical trials on cancer patients within two years.
Det europæiske ekspertpanel CHMP har været rundhåndet med de positive anbefalinger i juli. Blandt andet står antallet af godkendte lægemidler i den populære klasse af immunterapier rettet mod proteinparret PD-1/PD-L1 nu til at blive fordoblet i Europa. Samtidig fik en lang række storsælgende lægemidler udvidet potentialet.